OBJECTIVE: There is a close link between heart failure and endothelial dysfunction. Brachial flow-mediated dilation (FMD) is a validated non-invasive measure of endothelial function. The aim of this study was to investigate the clinical correlates of FMD in patients with chronic heart failure (CHF). DESIGN, SETTING, PATIENTS: We evaluated 60 CHF outpatients (age 62 ± 14 years; 49 males, NYHA class 2.2 ± 0.7, left ventricular ejection fraction, LVEF, 33 ± 8%) taking conventional medical therapy (ACE-inhibitors and/or ARBs 93%, beta-blockers 95%) and in stable clinical conditions. MAIN OUTCOME MEASURES: The maximum recovery value of FMD was calculated as the ratio of the change in diameter (maximum-baseline) over the baseline value. RESULTS: As compared with patients with a higher FMD, those with FMD below the median value (4.3%) were more frequently affected by ischemic cardiopathy (50 vs. 23%; p = 0.032) and diabetes mellitus (20 vs. 3%; p = 0.044), had a higher NYHA class (2.5 ± 0.5 vs. 1.9 ± 0.7; p < 0.001) and NT-proBNP (2,690 ± 3,690 vs. 822 ± 1,060; p = 0.001), lower glomerular filtration rate estimated by Cockcroft-Gault (GFRCG: 63 ± 28 vs. 78 ± 25; p = 0.001) and LVEF (29 ± 8 vs. 37 ± 9; p = 0.001), as well as more frequently showing a restrictive pattern (40 vs. 7%; p = 0.002). In a multivariate regression model (R (2) = 0.48; p < 0.001), FMD remained associated only with the NYHA class (p = 0.039) and diabetes mellitus (p = 0.024). CONCLUSIONS: This study demonstrates that a better functional status and absence of diabetes mellitus are associated to higher FMD regardless of the etiology of the cardiac disease.
OBJECTIVE: There is a close link between heart failure and endothelial dysfunction. Brachial flow-mediated dilation (FMD) is a validated non-invasive measure of endothelial function. The aim of this study was to investigate the clinical correlates of FMD in patients with chronic heart failure (CHF). DESIGN, SETTING, PATIENTS: We evaluated 60 CHF outpatients (age 62 ± 14 years; 49 males, NYHA class 2.2 ± 0.7, left ventricular ejection fraction, LVEF, 33 ± 8%) taking conventional medical therapy (ACE-inhibitors and/or ARBs 93%, beta-blockers 95%) and in stable clinical conditions. MAIN OUTCOME MEASURES: The maximum recovery value of FMD was calculated as the ratio of the change in diameter (maximum-baseline) over the baseline value. RESULTS: As compared with patients with a higher FMD, those with FMD below the median value (4.3%) were more frequently affected by ischemic cardiopathy (50 vs. 23%; p = 0.032) and diabetes mellitus (20 vs. 3%; p = 0.044), had a higher NYHA class (2.5 ± 0.5 vs. 1.9 ± 0.7; p < 0.001) and NT-proBNP (2,690 ± 3,690 vs. 822 ± 1,060; p = 0.001), lower glomerular filtration rate estimated by Cockcroft-Gault (GFRCG: 63 ± 28 vs. 78 ± 25; p = 0.001) and LVEF (29 ± 8 vs. 37 ± 9; p = 0.001), as well as more frequently showing a restrictive pattern (40 vs. 7%; p = 0.002). In a multivariate regression model (R (2) = 0.48; p < 0.001), FMD remained associated only with the NYHA class (p = 0.039) and diabetes mellitus (p = 0.024). CONCLUSIONS: This study demonstrates that a better functional status and absence of diabetes mellitus are associated to higher FMD regardless of the etiology of the cardiac disease.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack Shanewise; Scott Solomon; Kirk T Spencer; Martin St John Sutton; William Stewart Journal: Eur J Echocardiogr Date: 2006-02-02
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur J Heart Fail Date: 2008-09-16 Impact factor: 15.534
Authors: P Clarkson; D S Celermajer; A E Donald; M Sampson; K E Sorensen; M Adams; D K Yue; D J Betteridge; J E Deanfield Journal: J Am Coll Cardiol Date: 1996-09 Impact factor: 24.094
Authors: G H Guyatt; S O Pugsley; M J Sullivan; P J Thompson; L Berman; N L Jones; E L Fallen; D W Taylor Journal: Thorax Date: 1984-11 Impact factor: 9.139
Authors: L Agnoletti; S Curello; T Bachetti; F Malacarne; G Gaia; L Comini; M Volterrani; P Bonetti; G Parrinello; M Cadei; P G Grigolato; R Ferrari Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: H L Hillege; A R Girbes; P J de Kam; F Boomsma; D de Zeeuw; A Charlesworth; J R Hampton; D J van Veldhuisen Journal: Circulation Date: 2000-07-11 Impact factor: 29.690
Authors: Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege Journal: Clin Res Cardiol Date: 2008-10-31 Impact factor: 5.460
Authors: Monica Lisi; Matthias Oelze; Saverio Dragoni; Andrew Liuni; Sebastian Steven; Mary-Clare Luca; Dirk Stalleicken; Thomas Münzel; Franco Laghi-Pasini; Andreas Daiber; John D Parker; Tommaso Gori Journal: Clin Res Cardiol Date: 2012-06 Impact factor: 5.460
Authors: Frank van Buuren; Klaus Peter Mellwig; Christian Prinz; Britta Körber; Andreas Fründ; Dirk Fritzsche; Lothar Faber; Tanja Kottmann; Nicola Bogunovic; Johannes Dahm; Dieter Horstkotte Journal: Clin Res Cardiol Date: 2013-04-12 Impact factor: 5.460
Authors: G P T Areas; A Mazzuco; F R Caruso; R B Jaenisch; R Cabiddu; S A Phillips; R Arena; A Borghi-Silva Journal: Heart Fail Rev Date: 2019-01 Impact factor: 4.214
Authors: Britt Falskov; Thomas Steffen Hermann; Jakob Raunsø; Buris Christiansen; Christian Rask-Madsen; Atheline Major-Pedersen; Lars Køber; Christian Torp-Pedersen; Helena Dominguez Journal: Cardiovasc Diabetol Date: 2011-10-15 Impact factor: 9.951
Authors: Carmela Cosola; Maria De Angelis; Maria Teresa Rocchetti; Eustacchio Montemurno; Valentina Maranzano; Giuseppe Dalfino; Carlo Manno; Annapaola Zito; Michele Gesualdo; Marco Matteo Ciccone; Marco Gobbetti; Loreto Gesualdo Journal: PLoS One Date: 2017-01-20 Impact factor: 3.240